SCIENTIFIC PROGRAM

THURSDAY	14.11.2024
08:00-08:45	Registration
08:45-09:00	Welcome
09:00-11:05	Session 1: Basic science Chairpersons: Andrea Szuchman Sapir & Dov Gavish
09:00-09:15	Untargeted metabolomics reveals biomarkers for the diagnosis of coronary artery plaques as observed by coronary cardiac computed tomography Soliman Khatib Department of Nutrition and Natural Products, Migal, Tel-Hai
09:20-09:35	The Fluid Mechanics of Vascular Diseases and Localized Therapeutics Netanel Korin Department of Biomedical Engineering, Technion
09:40-09:55	Gene deletion of FAT10 modulates hepatic lipid metabolism during fasting and diet-induced de-novo lipogenesis in mice Yehuda Kamari The Bert W. Strassburger Lipid Center, Sackler Faculty of Medicine, Tel-Aviv University
10:00-10:30	Research award presentation (10 minutes each) Moran Yadid The Azrieli Faculty of Medicine, Bar-Ilan University, Safed Nethanel Zacks Department of Cardiology, Shaare-Zedek Medical Center Nitai Alter department of cardiology, Kaplan medical center
10:35-11:05	Key Note: A new SPRING in cholesterol metabolism: new functional and structural insight Noam Zelcer Department of Medical Biochemistry Academic Medical Center of the University of Amsterdam, The Netherlands
11:05-11:40	Coffee break
11:40-13:00	Session 2: Genetics of Lipid Disorders rather than Cardiovascular Chairpersons: Donna Zwas & Eran Leitersdorf
11:40-11:55	The Genetic link between Depression and Cardiovascular Disease in Premenopausal Women Arnon Blum Department of Medicine, Laniado Hospital
12:00-12:15	LDL Levels Elevated: Does Genetic Testing Make a Difference? Ronen Durst Hadassah Hebrew University Medical Center, Jerusalem

12:20-13:00	Cases in genetics of Lipid Disorders Atypical progeria Batya Green Family physician, CLALIT, Jerusalem Autosomal recessive combined lipase deficiency Gal Aviel Department of Cardiothoracic Surgery Hadassah Ein Karem ApoB-Related Familial Hypobetalipoproteinemia (FHBL) Eldad Rahamim Heart Institute, Hadassah Medical Center, Jerusalem
13:00 - 14:00	Lunch
14:00-14:30	Key note: The PCSK9 content in platelets of HeFH patients. Role in platelet functionality and the effect of anti-PCSK9 mAbs Alexandros Tselepis Emeritus Professor of Clinical Biochemistry, Atherothrombosis Research Centre / Department of Chemistry, University of Ioannina, Greece
14:35-14:50	Sustained LDL-C reduction in ASCVD, from long-term trials to real world implementation Dov Gavish Shaare Zedek Medical Center
14:50-16:30	Session 3: Non-conventional drivers and protectors of atherosclerosis Chairpersons: Yehuda Kamari & Ed Fisher
14:50- 15:00	Dynamic life style-induced changes in Asymmetric Dimethylarginine (ADMA) correlate with alteration in lipid profile and fasting insulin in subjects with the metabolic syndrome Bruria Tal The Sagol Center for the Metabolic Syndrome, Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center
15:05-15:35	Key note: Regression of atherosclerosis: many approaches to achieve the same goal Ed Fisher Leon H. Charney Professor of Cardiovascular Medicine, Director, Marc and Ruti Bell Vascular Biology Program, Director of Translational Research, The Center for the Prevention of Cardiovascular Disease Member, Cardiovascular Research Center, USA
15:40-15:55	The residual risk of ASCVD patient - what else can be done? Shlomi Matetzky Director Intensive Cardiac Care Unit & Deputy Director, Division of Cardiology at Sheba MC
16:00-16:30	Key note: Implementation research: The state of current management of the heightened risk for ASCVD events in a cohort of patients with lupus erythematosus Kevin Williams Cardiovascular Sciences, Professor of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, USA
17:30-19:00	Cocktail Party at the SEA HALL

FRIDAY, 15	.11.2024	
08:00-08:25	Registration	
08:25-08:30	Welcome	
08:30-10:10	Session 4: IHS ISA joint session Chairpersons: Alon Eisen & Barak Zafrir	
08:30- 08:45	ESC hypertension guidelines, what is new? Hadar Abramovich-Yoffe Rabin Medical Center	
08:50-09:05	Subclinical Atherosclerosis imaging – a key tool in primary Amir Aker Carmel Medical Center	prevention
09:10-09:25	LPa: Why is this important when there is no specific treat Barak Zafrir Carmel Medical Center	tment?
09:30-09:40	Richard J. Deckelbaum; in remembrance Ettie Granot Hebrew University – Hadassah, Medical School Kaplan Medical Center	
09:40-10:10	Lifetime Achievement Award to Prof. Eran Leitersdorf. My journey in atherosclerosis Prof. Ardon Rubinstein (Emeritus) Past head of the Israeli society of Arteriosclerosis	
10:10-10:40	Coffee Break	
10.10-10.40	Confee break	
10:40-10:55	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center	sm &
	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis	sm & M€DIS ⊘ N
10:40-10:55	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolic Hypertension, Tel-Aviv Sourasky Medical Center	M€DISØN
10:40-10:55 10:55-11:30	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center Session 5: Treating Homozygote FH Apheresis In HoFH Eldad J Dann Director of blood bank and Aphaeresis unit, RA	M€DISØN
10:40-10:55 10:55-11:30 10:55-11:10	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center Session 5: Treating Homozygote FH Apheresis In HoFH Eldad J Dann Director of blood bank and Aphaeresis unit, RA medical care center and Technion Pharmacotherapy In HoFH	M€DISØN
10:40-10:55 10:55-11:30 10:55-11:10 11:15-11:30	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center Session 5: Treating Homozygote FH Apheresis In HoFH Eldad J Dann Director of blood bank and Aphaeresis unit, RA medical care center and Technion Pharmacotherapy In HoFH Cohen Hofit Sheba Medical Center, Tel-Hashomer Session 6: Key aspects in atherosclerosis treatment	M€DISØN AMBAM
10:40-10:55 10:55-11:30 10:55-11:10 11:15-11:30	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center Session 5: Treating Homozygote FH Apheresis In HoFH Eldad J Dann Director of blood bank and Aphaeresis unit, RA medical care center and Technion Pharmacotherapy In HoFH Cohen Hofit Sheba Medical Center, Tel-Hashomer Session 6: Key aspects in atherosclerosis treatment Chairpersons: Avishai Elis & Elena Izkhakov How to prevent the first CV event	MEDIS N AMBAM Sanofi
10:40-10:55 10:55-11:30 10:55-11:10 11:15-11:30 11:30-12:50 11:30-11:45	Obesity diabetes GLP1 and atherosclerosis Roy Eldor Diabetes Unit Institute of Endocrinology, Metabolis Hypertension, Tel-Aviv Sourasky Medical Center Session 5: Treating Homozygote FH Apheresis In HoFH Eldad J Dann Director of blood bank and Aphaeresis unit, RA medical care center and Technion Pharmacotherapy In HoFH Cohen Hofit Sheba Medical Center, Tel-Hashomer Session 6: Key aspects in atherosclerosis treatment Chairpersons: Avishai Elis & Elena Izkhakov How to prevent the first CV event Dov Gavish Shaare Zedek Medical Center	MEDIS N AMBAM Sanofi











